This study aims to compare the levels of IL-2 between breast cancer patients and healthy women, and also compare the levels of IL-2 between HER-2 positive and HER-2 negative, ER/PR positive and ER/PR negative, and among different malignancy grades of breast cancer patients. Here, ESR1 is linked to breast carcinoma.